Skip to content
Clinical Trials – home
Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves adults with Type 2 Diabetes whose blood sugar levels are not well controlled despite taking metformin, with or without a Sodium-glucose cotransporter-2 inhibitor. Participants will receive either a monthly injection of Maridebart Cafraglutide or a weekly injection of Semaglutide in addition to their current medicines.

The aim is to see whether the monthly treatment works at least as well as the weekly treatment in lowering blood sugar, measured by changes in HbA1c and also looking at changes in body weight. After enrollment, participants will be assigned to one of the two injection schedules and will be followed for several months with regular clinic visits where blood samples and weight are taken to track progress.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit and Randomization

    You attend a baseline visit where your blood sugar level, weight, and other health information are recorded.

    Based on the study design, you are randomly assigned to receive either maridebart cafraglutide or semaglutide as an additional treatment to your current metformin therapy, with or without a SGLT-2 inhibitor.

  2. Step 2

    Start of Study Medication

    If you are assigned to the maridebart cafraglutide group, you will receive a subcutaneous injection of 00 mg once every four weeks (Q4W).

    If you are assigned to the semaglutide group, you will receive a subcutaneous injection of 00 mg once every week (QW).

    All injections are given under the skin using a pre‑filled syringe or pen as instructed by the study staff.

  3. Step 3

    Regular Follow‑Up Visits

    You will return to the clinic regularly for safety checks, blood tests, and measurements of weight and HbA1c (a laboratory test that shows average blood sugar over the past three months).

    The schedule typically includes a visit each month, but additional visits may occur if needed to adjust the study medication or address any concerns.

  4. Step 4

    Continuation of Study Medication

    You continue the assigned injection schedule for the entire study period while maintaining your usual dose of metformin and any SGLT-2 inhibitor you may be taking.

    The study medication is taken for approximately two years, from the start of the trial until the final study visit.

  5. Step 5

    Final Assessment

    At the end of the study, a final visit is conducted to record your last measurements of blood sugar control, weight, and any side effects.

    All data collected during the trial are used to compare the effectiveness and safety of the two study drugs.

Who can join the trial?

5 criteria

  • Be at least 18 years old (or the legal adult age in your country) when you sign the consent form.
  • Have a doctor‑confirmed diagnosis of type 2 diabetes (T2D) according to World Health Organization guidelines.
  • Be taking the diabetes medicine metformin at a dose of 1500 mg per day or the highest amount you can tolerate, and you may also be using a medicine called an SGLT‑2 inhibitor. Your dose of these medicines must have been steady for at least 90 days before you join the study.
  • Have a body‑mass index (BMI) of 25 kg/m² or higher when you are screened. (BMI is a simple calculation using your height and weight to estimate body fat.)
  • If you could become pregnant, you must use the type of birth control (contraception) required by the study during the treatment period and until the final study visit.

Who cannot join the trial?

18 criteria

  • Type 1 diabetes, a form of diabetes that is different from type 2, or a past history of severe high‑blood‑sugar emergencies such as ketoacidosis (dangerously high acids in the blood) or a hyperosmolar state/coma, or any other type of diabetes except type 2, or a history of diabetes during pregnancy (gestational diabetes).
  • A past or ongoing diagnosis of chronic pancreatitis, which is long‑term inflammation of the pancreas.
  • Having had an episode of acute pancreatitis (sudden inflammation of the pancreas) within the last 180 days before screening.
  • Any major heart or blood‑vessel problem in the past 60 days, such as a heart attack (myocardial infarction, MI), heart‑bypass surgery (CABG) or other major heart surgery, stroke, hospitalization for unstable chest pain (unstable angina), heart failure, or a brief loss of brain blood flow (transient ischemic attack, TIA).
  • Having the most severe level of heart failure, called NYHA Class IV heart failure.
  • Using any medication that lowers blood sugar (other than metformin or an SGLT‑2 inhibitor) within 90 days before randomization, or using weight‑loss drugs, long‑term steroid medicines (systemic glucocorticoids), or medicines that cause a lot of weight gain (such as certain antidepressants, antipsychotics, or mood stabilizers) unless the dose was unchanged for at least 90 days.
  • Abnormal thyroid test results: a thyroid‑stimulating hormone (TSH) level lower than 0.4 mIU/L, or higher than 6.0 mIU/L together with low free thyroxine (the active thyroid hormone), unless thyroid medication has been stable for at least 90 days and the test is within the allowed range.
  • Very reduced kidney function, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², or being on dialysis at the time of screening.
  • Active liver disease such as acute or chronic hepatitis, or liver enzyme levels that are markedly high (alanine aminotransferase ALT more than three times the normal upper limit or total bilirubin > 1.2 times normal).
  • Being currently pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period and for a short time after the last dose.
  • Receiving or planning to receive eye treatments for diabetes‑related eye problems (such as laser therapy or eye injections) during the trial.
  • Having advanced diabetic eye disease, including proliferative diabetic retinopathy, diabetic maculopathy, or severe non‑proliferative diabetic retinopathy.
  • Having experienced a serious low‑blood‑sugar event (Level 3 hypoglycemia) that required help from another person within the past 180 days.
  • Having a history of not recognizing low‑blood‑sugar symptoms (hypoglycemia unawareness) or poor awareness of such symptoms.
  • Having lost or gained more than 5 % of body weight in the 90 days before screening, and being unwilling to avoid starting an intensive diet or exercise program aimed at weight loss during the trial.
  • Having had or planning to have any surgical, endoscopic, or device‑based treatment for obesity (weight‑loss surgery or devices).
  • Known allergy or intolerance to the study drug or any of its ingredients.
  • A diagnosis of cancer (malignancy) within the last 5 years, except for certain early skin cancers, non‑invasive breast cancer (ductal carcinoma in situ), or early cervical cancer (carcinoma in situ) that were treated with curative intent.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Maridebart Cafraglutide
Maridebart Cafraglutide is an experimental injectable medicine that is given under the skin once a month. In this study it is being tested to see if it can lower blood sugar in people with type 2 diabetes when added to their usual diabetes pills. The drug works by helping the pancreas release more insulin after meals and by slowing down the amount of sugar that the liver makes. Semaglutide
Semaglutide is a well‑known injectable medicine that is taken under the skin once a week. In the trial it is used as the comparison treatment to see how it performs against Maridebart Cafraglutide. Semaglutide also helps the body release more insulin after eating and reduces the amount of sugar the liver produces, which helps lower blood glucose levels. Metformin
Metformin is an oral medication that many people with type 2 diabetes take every day. It works mainly by decreasing the amount of glucose the liver releases and by making the body’s cells more sensitive to insulin. In this study all participants continue their regular metformin therapy while the new injectable medicines are added. Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor
An SGLT‑2 inhibitor is a class of pills that help the kidneys remove extra sugar from the blood through the urine. Some participants in the trial are also taking an SGLT‑2 inhibitor along with metformin, which can further improve blood‑sugar control. The study looks at how the new injectable drugs work when they are added to this combination of medicines.

What is already known about the treatment

  • Maridebart Cafraglutide

    This investigational drug is given as a solution for injection under the skin once a month. It is still in clinical trials and not yet approved for general medical use, so information about it is limited to research reports. It is being studied for people with type 2 diabetes whose blood sugar is not well controlled with metformin, with or without an SGLT‑2 inhibitor. The medicine works by copying a natural hormone called GLP‑1, which helps the pancreas release insulin and lowers the amount of sugar produced by the liver; it belongs to the class of GLP‑1 receptor agonist peptides.

  • Semaglutide

    This approved medication is injected under the skin once a week as a liquid solution. It is widely used and well documented in medical literature for the treatment of type 2 diabetes and for weight management. It helps lower blood sugar by acting like the body’s own GLP‑1 hormone, stimulating insulin release after meals and reducing glucose production by the liver. Semaglutide is classified as a GLP‑1 receptor agonist, a type of peptide drug.

Investigated diseases

Type 2 diabetes mellitus inadequately controlled with metformin, with or without a sodium‑glucose cotransporter‑2 inhibitor - Type 2 diabetes mellitus is a chronic condition in which the body does not use insulin properly, leading to high blood sugar. When metformin does not keep blood sugar at target, the disease may continue to worsen over time. Blood sugar levels can rise gradually, causing increased thirst, frequent urination, and fatigue. If not adequately managed, the condition can spread to affect the pancreas, liver, and blood vessels. The disease often progresses from mild elevation of glucose to higher levels that require additional medication. Regular monitoring of blood sugar helps to track its course.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-523772-22-00Protocol code20230220Estimated enrolment836 patientsSponsorAmgen Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.